SPDR S&P Biotech ETF
Price through Oct 6, 2026 · Flows through Oct 5, 2026. Figures use the latest available records, not a live quote. Fund details retrieved Oct 6, 2026. Holdings snapshot retrieved Oct 6, 2026.
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 6M SHOWN · NET +$112M OVER THIS RANGE
Money is leaving — −$567M in net outflows over the past month, about 5.5% of the fund's asset base, while the price has returned +23.8% so far this year. At 0.35% a year it is not the cheapest way in — IWM has a reported fee of 0.19%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | MRNAMODERNA | 1.41% | $187.46 | -7.8% | ||
| 2 | TWSTTWIST BIOSCIENCE | 1.40% | $166.97 | -18.6% | ||
| 3 | GRALGRAIL INC | 0.90% | $137.28 | -10.9% | ||
| 4 | IOVAIOVANCE BIOTHERAPEUTICS | 0.56% | $12.96 | -8.4% | ||
| 5 | NTRANATERA | 1.16% | $400.65 | -5.9% | ||
| 6 | HALOHALOZYME THERAPEUTICS | 1.03% | $109.72 | +1.3% | ||
| 7 | PCVXVAXCYTE | 1.18% | $66.70 | -9.6% | ||
| 8 | KODKODIAK SCIENCES | 0.54% | $92.34 | -1.6% | ||
| 9 | RVMDREVOLUTION MEDICINES | 1.20% | $199.87 | -3.8% | ||
| 10 | KYMRKYMERA THERAPEUTICS | 1.35% | $105.98 | -3.5% | ||
| 11 | PTGXPROTAGONIST THERAPEUTICS | 1.07% | $138.69 | -1.4% | ||
| 12 | SMMTSUMMIT THERAPEUTICS | 1.01% | $17.31 | +0.2% | ||
| 13 | ORKAOruka Therapeutics | 1.37% | $80.18 | -5.0% | ||
| 14 | ROIVROIVANT SCIENCES | 1.15% | $35.53 | -0.7% | ||
| 15 | REGNREGENERON PHARMACEUTICALS | 0.96% | $738.72 | +1.7% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus CSV export, watchlists, and flow alerts — unlock across the network.
Sign in to see all 135| 1 week | -4.3% |
| 1 month | -7.9% |
| 3 months | -6.2% |
| 6 months | +17.0% |
| YTD | +23.8% |
| 1 year | +45.6% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | −$140M |
| 1 month | −$567M |
| 3 months | −$272M |
| YTD | +$343M |
| 1 year | +$935M |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
The top holding is 1.5% of the book; the top ten carry 13%. Spread across 151+ names, it behaves like roughly 110 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| MRNA MODERNA | $52M | $54M |
| TWST TWIST BIOSCIENCE | $8M | $10M |
| SLS SELLAS LIFE SCIENCES GROUP | $4M | $6M |
| ABBV ABBVIE | $4M | $4M |
| INSM INSMED | $5M | $2M |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
Due diligence cuts both ways. These funds sit on the same shelf and beat XBI on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| SPDW State Street SPDR Portfolio Developed World ex-US ETF | 0.03% | $41B | +$286M | -32bp on fee · 4× the assets · +$286M in over the month | Head-to-head |
| SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.03% | $18.4B | +$199M | -32bp on fee · 2× the assets · +$199M in over the month | Head-to-head |
| IDEV iShares Core MSCI International Developed Markets ETF | 0.04% | $32.4B | +$497M | -31bp on fee · 3× the assets · +$497M in over the month | Head-to-head |
| IGSB iShares 1-5 Year Investment Grade Corporate Bond ETF | 0.04% | $23.3B | +$575M | -31bp on fee · 2× the assets · +$575M in over the month | Head-to-head |
| IGIB iShares 5-10 Year Investment Grade Corporate Bond ETF | 0.04% | $18.6B | +$412M | -31bp on fee · 2× the assets · +$412M in over the month | Head-to-head |